Jupiter Neurosciences Signs $100 Million License Agreement with PharmAla Biotech

Jupiter Neurosciences (NASDAQ:JUNS) signed a licensing agreement for exclusive U.S. rights to ALA-002, valued up to $100 million including upfront and milestone payments. The deal expands Jupiter's pipeline into neuropsychiatric disorders with this clinical-stage psychedelic therapeutic candidate.

By Fiona Craig Tue, July 21, 2026 at 5:27 PM GMT+3 4 min read · Yahoo Finance · July 21, 2026, 14:27 UTC

Jupiter Neurosciences Signs $100 Million License Agreement with PharmAla Biotech

Topics: CNS Therapeutics Pharmaceuticals Psychedelic Medicine

Read the full article at Yahoo Finance

More World news

Hugging Face CEO Reaffirms Commitment to Open-Source AI Following Nvidia CEO Jensen Huang's Departure TechCrunch · November 12, 2026, 17:36 UTC
Marimed Reports Record $44.2M Quarterly Revenue and Targets 2027 New York Launch Seeking Alpha · November 12, 2026, 17:30 UTC
Nebius Group Reports Massive Q3 2026 Revenue Growth Driven by AI Cloud Expansion Motley Fool · November 12, 2026, 17:29 UTC
Reagan Institute Launches Society of Fellows to Support Early Career Scholars PR Newswire · November 12, 2026, 17:32 UTC
Global Asset Management Group Signs LOI for $100 Million Affordable Housing Portfolio in Washington, D.C. PR Newswire · November 12, 2026, 17:30 UTC
U.S. Air Conditioner and Heat Pump Shipments Increase 27.3% in September Seeking Alpha · November 12, 2026, 17:27 UTC
Nvidia CEO Jensen Huang Resigns Amid Intelligence Probe Seeking Alpha · November 12, 2026, 17:27 UTC
Oklo and Centrus Energy Sign Multi-Year HALEU Fuel Supply Agreements for Ohio Nuclear Campus Seeking Alpha · November 12, 2026, 17:28 UTC
IRS Announces Increased 401(k) Contribution Limits for 2027 CNBC · November 12, 2026, 17:23 UTC
Bit Digital Announces $865 Million Contract and Commencement of 40MW Billing Seeking Alpha · November 12, 2026, 17:20 UTC